Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp (TECH) revenue by segment, product and region

	Q4 FY2026	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024
Consumables	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Instruments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Services	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Royalty	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Product and Services	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Bio-Techne Corp (TECH) revenue by segment, product and region

Stockrow Weekly